Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling

Fig. 5

Silence of miR-301b enhances the anti-cancer effect of ISL on melanoma in vivo. A2058 cells were implanted subcutaneously into immunocompromised mice. When the tumors reached 80 mm3 in volume, the mice received intratumoral administration of miR-301b angomir or corresponding negative control and intraperitoneal administration of ISL every other day. The tumors were excised 42 days after treatment for analysis. a Representative images of tumor form in each group. b-d Quantification of volume, weight and growth curve of tumors in each group. e Representative images of H&E staining and immunohistochemical staining of Ki67 and TUNEL in tumor sections of each group. f-g Quantification of percentage of Ki67 and TUNEL positive cells in tumor sections. *P < 0.05, **P < 0.01, ***P < 0.001, n = 3

Back to article page